menu
Intellia Therapeutics Head office building

Press Releases

FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015

Cambridge, MA – September 30, 2015 – Intellia Therapeutics has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "We're honored to be named to the 2015 "Fierce 15" Biotech
Read More

Intellia Therapeutics Secures $70 Million in Series B Financing

Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology Pipeline Primarily Focused on Disorders of the Liver and Blood CAMBRIDGE, Mass., Sept. 1, 2015 – Intellia Therapeutics, a leading gene-editing company focused on the development of
Read More

Intellia Statement on Germline Editing

In May, both the National Institutes of Health (NIH) and the White House voiced concern over ethical issues associated with using gene-editing technology to alter the human germline. The White House Office of Scientific Assessment further stated that, "the Administration believes that altering the
Read More

Intellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance and Strategy Officer

CAMBRIDGE, Mass., April 22, 2015 —Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, announced today the appointment of Dr. Sapna Srivastava as Chief Financial and Strategy Officer.
Read More

Intellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company

CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 for gene editing and repair, announced today that Jennifer Doudna, PhD, and Derrick Rossi, PhD, will join Intellia as founding members and scientific advisors of the Company. Dr.
Read More

Intellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology

Five-Year Collaboration Focused on CART and Hematopoetic Stem Cell Applications across a Range of Therapeutic Areas CAMBRIDGE, Mass.—January 7, 2015—Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a
Read More

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment
Read More
RSS FEEDS
PRINT PAGE